Silence Cravings & Burn Fat With The First Clinically Proven Natural GLP-1 Alternative.

What was studied

A randomized, double-blind, crossover clinical trial at the University of Auckland and Plant & Food Research New Zealand. Nineteen healthy-weight men received either 500mg of Amarasate hops extract (delivered to the stomach or duodenum) or placebo on three occasions with one-week washouts. After each dose, researchers measured blood levels of GLP-1, CCK, PYY, and ghrelin, and recorded food intake at a standardized lunch.

Key Findings

• Both gastric and duodenal hops delivery significantly increased GLP-1, CCK, and PYY — the three primary satiety hormones
• Participants ate significantly less at the ad libitum test meal versus placebo
• Effect attributed to bitter taste receptors (TAS2Rs) on gut enteroendocrine cells
• Notably: subjective hunger ratings didn't change much — yet participants still ate less. A "bitter brake" mechanism operating below conscious appetite

What was studied

Researchers at the University of Illinois tested 27 different flavonoids and phenolic compounds — the kind found in berries, citrus, and grapes — for their ability to inhibit DPP-4, the enzyme that breaks down GLP-1 within minutes of secretion. Each compound was measured both in laboratory enzyme assays and through computational docking analysis.

Key Findings

• Luteolin showed an IC50 of 0.12 μM — in the top tier of natural DPP-4 inhibitors tested
• 35× more potent than diprotin A, the pharmaceutical reference compound (IC50 4.21 μM)
• Computational modeling confirmed luteolin docks into the S2 and S3 active pockets of DPP-4
• Inhibition is non-competitive — luteolin keeps working regardless of how much GLP-1 is being produced

What was studied

A Taiwanese team used a multi-stage discovery pipeline: molecular docking to screen phenolic compounds for DPP-4 binding affinity, in vitro enzymatic assays to confirm inhibition, cell culture studies in intestinal, muscle, and pancreatic cells, and finally in vivo testing in diet-induced diabetic mice to confirm long-term safety and efficacy.

Key Findings

• Multiple natural phenolic compounds bind directly to DPP-4 with measurable inhibitory activity
• Curcumin and resveratrol both demonstrated strong inhibition in enzymatic tests
• Diabetic mice showed reduced blood glucose and long-term HbA1c regulation with phenolic supplementation
• Confirms the class effect: natural polyphenols — DHM, EGCG, curcumin, resveratrol — genuinely inhibit DPP-4

What was studied

A prospective, randomized, double-blind, placebo-controlled trial at the University of Mississippi Medical Center. Eighty adults with elevated cholesterol were randomized to one of four arms: 125mg pterostilbene twice daily, 50mg twice daily, 50mg plus grape extract 100mg twice daily, or placebo — for 6–8 weeks. Researchers tracked lipids, blood pressure, body weight, and safety markers.

Key Findings

• Significant systolic blood pressure reduction (−7.8 mmHg) at the high dose
• Significant diastolic blood pressure reduction (−7.3 mmHg)
• Minor but measurable weight loss in non-medicated patients (−0.62 kg/m² BMI)
• No adverse drug reactions on hepatic, renal, or glucose markers across any arm
• 91.3% completion rate — well-tolerated at all doses

What was studied

Researchers at Cedars-Sinai combined four methods: immunohistochemistry on human ileum tissue to locate the bitter taste receptor TAS2R38, virtual screening of ~2.5 million compounds for TAS2R38 binding affinity, in vitro testing of top hits in HuTu-80 cells (with TAS2R38 knockout controls), and in vivo animal studies. The hypothesis: bitter receptors in the gut could be activated to trigger GLP-1 release without entering the bloodstream.

Key Findings

• TAS2R38 receptors were confirmed co-localized with GLP-1 in human L-cells of the ileum
• TAS2R38 agonists stimulated GLP-1 release dose-dependently in cell cultures
• Knockout studies showed dramatically reduced GLP-1 response without TAS2R38 — confirming the receptor's role
• In vivo studies confirmed gut-local activation works without systemic absorption

What was studied

A foundational pharmacokinetic study testing whether piperine — the active alkaloid in black pepper, known to inhibit hepatic and intestinal glucuronidation — could enhance curcumin's notoriously poor oral bioavailability. Researchers measured serum curcumin concentrations at multiple time points after dosing, in both rats and healthy human volunteers.

Key Findings

• Curcumin alone has extremely poor oral bioavailability — most is metabolized before reaching circulation
• Piperine blocks the enzymes responsible for curcumin's rapid breakdown
• Combined dosing produced a 2,000% increase in curcumin bioavailability in human volunteers
• Peak curcumin concentration arrives ~45 minutes after co-administration with piperine
• No adverse effects observed at the studied dosages